NovaSight
Eye-Tracking Based Solutions for Pediatric Vision Care
Company Overview
Snapshot
Founded in February 2016 by Danny Oz, NovaSight is a Health Tech & Life Sciences company with 11–50 employees. The company has raised $38.88 million across 6 funding rounds from 10 investors. In March 2024, NovaSight secured a funding round led by Infinity China.
Business overview
NovaSight is a medical device company dedicated to preventing vision impairments in pediatric patients through eye-tracking based technology. The company develops novel diagnostic, therapeutic, and preventive solutions tailored for children's unique needs, focusing on vision treatment, diagnostics, and monitoring. Its flagship product, CureSight™, is an FDA-cleared and CE-marked amblyopia treatment system that replaces traditional eye patching by blurring the dominant eye's vision while the patient watches streamed content, stimulating the amblyopic eye. NovaSight also offers EyeSwiftPRO for automated vision testing and is developing TrackSight™, a SaaS solution for myopia prevention and visual health monitoring for both children and adults.
Strategic signal
In September 2024, a study published in the American Journal of Ophthalmology demonstrated NovaSight's CureSight digital eye-tracking system to be superior to traditional patching methods for treating amblyopia, showing significant improvements in visual acuity and adherence. This validation underscores the efficacy and patient-centric benefits of NovaSight's technology, signaling strong potential for market adoption and further growth in pediatric vision care.
Log in to access full profile ›Company Intelligence Q&A
- What is CureSight and what does it do?
- CureSight is NovaSight's FDA-cleared and CE-marked amblyopia (lazy eye) treatment system. It replaces traditional eye patching by using eye-tracking technology to blur the dominant eye's vision while the patient watches streamed content, encouraging the amblyopic eye to improve its acuity.
- When did NovaSight last raise funding?
- In March 2024, NovaSight secured a funding round led by Infinity China.
- What significant clinical validation did CureSight receive in late 2024?
- In September 2024, a study published in the American Journal of Ophthalmology demonstrated CureSight's superiority over traditional patching for amblyopia treatment, showing improved visual acuity and adherence rates.
- What are NovaSight's other key products?
- Beyond CureSight, NovaSight offers EyeSwiftPRO for automated vision testing and is developing TrackSight™, a software-as-a-service solution for myopia prevention and visual health monitoring.